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Abstract
Background The EORTC QLU-C10D is a new multi-at-
tribute utility instrument derived from the widely used
cancer-specific quality-of-life (QOL) questionnaire,
EORTC QLQ-C30. The QLU-C10D contains ten dimen-
sions (Physical, Role, Social and Emotional Functioning;
Pain, Fatigue, Sleep, Appetite, Nausea, Bowel Problems),
each with four levels. To be used in cost-utility analysis,
country-specific valuation sets are required.
Objective The aim of this study was to provide Australian
utility weights for the QLU-C10D.
Methods An Australian online panel was quota-sampled to
ensure population representativeness by sex and age
(C 18 years). Participants completed a discrete choice
experiment (DCE) consisting of 16 choice-pairs. Each pair
comprised two QLU-C10D health states plus life expec-
tancy. Data were analysed using conditional logistic
regression, parameterised to fit the quality-adjusted life-
year framework. Utility weights were calculated as the
ratio of each QOL dimension-level coefficient to the
coefficient on life expectancy.
Results A total of 1979 panel members opted in, 1904
(96%) completed at least one choice-pair, and 1846 (93%)
completed all 16 choice-pairs. Dimension weights were
generally monotonic: poorer levels within each dimension
were generally associated with greater utility decrements.
The dimensions that impacted most on choice were, in
order, Physical Functioning, Pain, Role Functioning and
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Emotional Functioning. Oncology-relevant dimensions
with moderate impact were Nausea and Bowel Problems.
Fatigue, Trouble Sleeping and Appetite had relatively
small impact. The value of the worst health state was -
0.096, somewhat worse than death.
Conclusions This study provides the first country-specific
value set for the QLU-C10D, which can facilitate cost-
utility analyses when applied to data collected with the
EORTC QLQ-C30, prospectively and retrospectively.
Key Points for Decision Makers
This study provides the first value set (i.e. set of
utility weights) for the EORTC QLU-C10D, a new
preference-based multi-attribute utility instrument
derived from the widely used cancer-specific quality-
of-life questionnaire, EORTC QLQ-C30.
Cost-utility analysis (CUA) represents a major part
of the reimbursement process in many countries. The
availability of the EORTC QLU-C10D will facilitate
CUA for cancer interventions, as it can be applied to
data collected with the EORTC QLQ-C30,
prospectively and retrospectively.
Sizeable utility decrements associated with cancer-
sensitive dimensions, notably nausea, bowel
problems and appetite, may make the QLU-C10D
more sensitive than generic measures in CUA.
Future research is required to assess this in datasets
containing both the QLQ-C30 and a generic utility
instrument.
1 Introduction
Economic evaluation is central to the evaluation of new
therapies and technologies in many countries. Cost-utility
analysis (CUA) is a form of economic evaluation that
quantifies health outcomes on a standardised metric, typi-
cally the quality-adjusted life-year (QALY). The quality
adjustment is provided by a ‘value set’; that is, a set of
utility weights for a range of possible health states within
any given health state classification system. Value sets can
be derived for classification systems originally developed
as multi-attribute utility instruments (MAUI), or by adap-
tation of existing health-related quality of life (HRQoL)
profile measures [1, 2]. Such a measure, the EORTC QLQ-
C30, is a widely used core questionnaire in the modular
HRQoL suite of the European Organisation for Research
and Treatment of Cancer (EORTC) [3].
The Multi-Attribute Utility in Cancer (MAUCa) Con-
sortium aims to facilitate the use of HRQoL data in CUA in
cancer settings by providing a series of country-specific
value sets for the QLQ-C30. To this end, we have devel-
oped a health state classification system containing 13 of
the QLQ-C30’s 30 items, combined into ten dimensions
(Table 1) [4] and a valuation method based on a discrete
choice experiment (DCE) [5]. These are key components of
the QLU-C10D, a new cancer-specific MAUI. The aim of
this current paper is to apply the valuation method in an
Australian general population sample to produce the first
country-specific utility weights for the QLU-C10D.
2 Methods
2.1 The QLU-C10D
Table 1 shows the QLU-C10D health state classification
system, and explains how the ten dimensions, each with
four levels, map to 13 of the 30 items in the QLQ-C30. The
derivation of this health state classification system is
described elsewhere [4].
2.2 The Valuation Task: Discrete Choice
Experiment (DCE) Presentation
The valuation task was based on methods developed for the
Australian valuations for the EQ-5D(3L) and SF-6D
instruments [6, 7]. The task involved choosing between two
QLU-C10D health states, each with a specified duration
(life years), described as ‘Situation A’ and ‘Situation B’
(Fig. 1). Because the QLU-C10D includes more dimen-
sions than the EQ-5D(3L) or SF-6D, we first established
the feasibility of the task, and pilot tested the DCE task
wording, layout and presentation formats [5]. Choice sets
were presented in a format preferred by participants in the
QLU-C10D valuation methods experiment [5]; that is,
dimensions that differed between situations A and B were
highlighted in yellow. For the Physical Functioning
dimension, the descriptors for levels 2 and 3 are quite
complex (Table 1). To facilitate respondent understanding,
we presented the two component items, ‘long walk’ and
‘short walk’, as two separate attributes in the survey
(Fig. 1). Note that the Physical Functioning dimension was
treated as one four-level dimension in the DCE design
(online resource 1, see electronic supplementary material
[ESM]) and data analysis.
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Table 1 The QLU-C10D health state classification system, how it maps to the 13 component items from the QLQ-C30, and the duration
attribute included in the discrete choice experiment (DCE) valuation survey
Dimension Level Stem Descriptor QLQ-C30 item scores
Physical
functioninga,b
1 You have… No trouble taking a long walk outside of
the house
Item 2 (long walk) = 1
2 No trouble taking a short walk outside of
the house, but at least a little trouble
taking a long walk
Item 3 (short walk) = 1 AND
Item 2C 2
3 A little trouble taking a short walk outside
of the house, and at least a little trouble
taking a long walk
Item 3 = 2 AND
Item 2C 2
4 Quite a bit or very much trouble taking a
short walk outside the house
Item 3C 3 AND
Item 2C 2
Role functioning 1 You are limited in pursuing your
work or other daily activities…
Not at all Item 6 = 1
2 A little Item 6 = 2
3 Quite a bit Item 6 = 3
4 Very much Item 6 = 4
Social functioninga,c 1 Your physical condition or
medical treatment interferes with
your social or family life…
Not at all Items 26 AND 27 = 1
2 A little Items 26 OR 27 = 2c
3 Quite a bit Items 26 OR 27 = 3c
4 Very much Items 26 OR 27 = 4c
Emotional
functioning
1 You feel depressed… Not at all Item 24 = 1
2 A little Item 24 = 2
3 Quite a bit Item 24 = 3
4 Very much Item 24 = 4
Pain 1 You have pain… Not at all Item 9 = 1
2 A little Item 9 = 2
3 Quite a bit Item 9 = 3
4 Very much Item 9 = 4
Fatigue 1 You feel tired… Not at all Item 18 = 1
2 A little Item 18 = 2
3 Quite a bit Item 18 = 3
4 Very much Item 18 = 4
Sleep 1 You have trouble sleeping… Not at all Item 11 = 1
2 A little Item 11 = 2
3 Quite a bit Item 11 = 3
4 Very much Item 11 = 4
Appetite 1 You lack appetite… Not at all Item 13 = 1
2 A little Item 13 = 2
3 Quite a bit Item 13 = 3
4 Very much Item 13 = 4
Nausea 1 You feel nauseated… Not at all Item 14 = 1
2 A little Item 14 = 2
3 Quite a bit Item 14 = 3
4 Very much Item 14 = 4
Bowel problemsa,c 1 You… Do not have constipation or diarrhoea at
all
Items 16 AND 17 = 1
2 Have a little constipation or diarrhoea Items 16 OR 17 = 2c
3 Have constipation or diarrhoea quite a bit Items 16 OR 17 = 3c
4 Have constipation or diarrhoea very much Items 16 OR 17 = 4c
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Table 1 continued
Dimension Level Stem Descriptor QLQ-C30 item scores
Duration 1 You will live in this health state
for…
1 year, and then die Not applicable
2 2 years, and then die Not applicable
3 5 years, and then die Not applicable
4 10 years, and then die Not applicable
aThree dimensions of the QLU-C10D each involve two QLQ-C30 items
bThe Physical Functioning dimension includes ‘long walk’ and ‘short walk’ from the QLQ-C30; for the DCE, the levels are determined together,
but were presented in the DCE survey separately, as shown in Fig. 1
cFor social functioning and bowel problems, the QLU-C10D level is determined by the maximum value of the two component items
Fig. 1 An example choice set from the discrete choice experiment valuation task
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2.3 Health States Valued: DCE Design
The QLU-C10D health state classification system has
over a million possible health states (410 = 1,048,576).
We employed a designed experiment to select 960
choices sets that would maximise statistical efficiency in
estimating the utility model parameters. Health states
were operationalised as 12 attributes in the DCE: one for
duration, two to represent physical functioning (long and
short walk), and one for each of the remaining nine
QLU-C10D dimensions. Because 12 dimensions is a
relatively large number for respondents to consider
simultaneously, we simplified the cognitive task by
constraining the number of HRQoL dimensions that
differed between health states in any given choice set to
four, as done in the QLU-C10D valuation methods
experiment [5], using the same experimental design.
Briefly, we began with a balanced incomplete block
design (BIBD) to define which four of the ten QLU-
C10D dimensions differed within choice sets [8]. This
BIBD was then duplicated. To determine the levels of
these differing dimensions, a generator-based approach
was employed, designed to allow estimation of main
effects and all two-factor interactions involving duration
[9]. The levels of the six dimensions that were constant
between options were then developed using an orthogo-
nal main effects plan. This follows the approach outlined
by Demirkale et al. [10]. The final design comprised
1920 health states in 960 choice sets (online resource 1,
see ESM).
There were two levels of randomisation in the DCE
component of the survey: (i) each respondent was ran-
domly allocated 16 of the 960 choice sets without
replacement; (ii) which option was seen as Situation A or B
was randomised within each choice set to mitigate any
ordering bias. The dimensions were always presented in the
same order, as previous work showed that dimension order
does not systematically bias utility weights for the QLU-
C10D [11].
2.4 Survey Content
All survey content was developed by the MAUCa
Consortium. In addition to the DCE, the survey con-
tained other components (Fig. 2). The self-reported
health questions included the general health question of
the SF-36 [12] and the Kessler-10 (mental health)
questionnaire [13]. Sociodemographic questions were
worded such that they could be mapped directly to
normative data to enable assessment of our sample’s
representativeness of the Australian general population
(Table 2).
2.5 Survey Implementation and Sample
Recruitment
The content was implemented as an online survey by
SurveyEngine [14], a company that specialises in choice
experiments. SurveyEngine and its panel providers comply
with the International Code on Market, Opinion and Social
Research and Data Analytics [15]. SurveyEngine managed
recruitment (via an Australian online panel provided by
Toluna), administration of the survey and data collection.
The target population was the Australian adult general
population (agedC 18 years). Participants were panel
members aged 18 years or older who opted in to the sur-
vey. There were no exclusion criteria. Quota sampling by
age and sex was used to achieve population representa-
tiveness on those variables.
2.6 Statistical Analysis
2.6.1 Sample Representativeness
Chi-square tests were used to assess our sample’s repre-
sentativeness of the Australian population for age and sex
(population data available from the Australian Bureau of
Statistics as at March 2013 [16]); self-reported general
health, Aboriginal and Torres Strait Islander (ATSI) status,
highest level of education, and country of birth (population
data available from the Household, Income and Labour
Dynamics in Australia Surveys [HILDA], Wave 10 [17]);
self-reported mental health (Kessler-10 Australian norms
from the 2007 Australian National Health Survey [18]).
2.6.2 Utility Estimation
The DCE data were analysed in the statistical software
package STATA-13 [19] using a functional form used
previously to estimate utilities from DCE data consistent
with standard QALY model restrictions [5–7, 20, 21]. The
QALY model requires that all health states have zero utility
at death (i.e. ‘the zero condition’) [22, 23]. A functional
form that satisfied this requirement included the QLU-
C10D dimension levels interacted with the duration vari-
able (‘TIME’) (Eqs. 1, 2). Thus, as TIME tended to zero,
the systematic component of the utility function tended to
zero. Another requirement of the QALY model is constant
proportional time trade-off, therefore the relationship
between utility and TIME (life years) was constrained to be
linear.
A useful feature of this functional form was that the
impact of moving away from level 1 (no problems) in each
dimension was characterised through the two-factor inter-
action term with duration (note that the experimental
design allowed for all these interactions). This enabled a
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utility algorithm in which the effect of each level of each
dimension could be included as a decrement away from full
health (which had a value of 1).
We analysed the data in two ways, reflecting different
approaches to modelling heterogeneity (Eqs. 1, 2). The
primary analysis was underpinned by Eq. 1, in which the
utility of option j in choice set s for survey respondent i was
assumed to be
Uisj ¼ aTIMEisj þ bX 0isjTIMEisj þ eisj
i ¼ 1; . . .; I respondents; j ¼ situations A;
B; s ¼ 1; . . .; 960 choice sets
ð1Þ
where a was the utility associated with a life year, X
0
isj was
a vector of dummy variables representing the levels of the
QLU-C10D health state presented in option j, and b was
Fig. 2 Respondent flow and
sample size for each component
of the survey. DCE discrete
choice experiment
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the corresponding vector of utility weights associated with
each level in each dimension within X
0
isj, for each life year.
The error term eisj was assumed to have a Gumbel
distribution.
In the primary analysis, DCE responses were estimated
as a conditional logit model. To adjust the standard errors
to allow for intra-individual correlation (as each respondent
was asked to consider 16 DCE choice sets), we used a
clustered sandwich estimator implemented by STATA’s
vce (cluster) option. To estimate utility decrements for
each movement away from level 1 (no problems) in each of
the ten QLU-C10D dimensions, we divided each of the b
terms by a. To estimate confidence intervals around these
ratios, we used STATA’s wtp command [23], using the
delta method.
Model 1 included every move away from the best level
(level 1, no problems) in each dimension within X
0
isj. Thus,
X
0
isj contained 30 terms (i.e. 10 dimensions 9 [4-1] levels
within each). If non-monotonicity was observed among
Table 2 Self-reported health and sociodemographic characteristics of the sample compared with those of the Australian general population
Question Level Number Proportion (or mean, x) Population value Statistica p value
Sex Male 913 0.49 0.49 V2 = 0.007 0.93
Female 943 0.51 0.51
Age (years) 18–29 409 0.22 0.22 V2 = 0.92 0.97
30–39 334 0.18 0.18
40–49 325 0.18 0.18
50–59 301 0.16 0.17
60–69 243 0.13 0.13
70 or older 243 0.13 0.13
General Health Question (GHQ) Excellent 206 0.10 0.10 V2 = 31.4 \0.0001
Very good 635 0.32 0.35
Good 703 0.36 0.37
Fair 343 0.17 0.15
Poor 92 0.05 0.03
Mental health Kessler-10 1822 x = 17.81 l = 14.50 t = 18.0 \0.0001
Country of Birth Australia 1359 0.74 0.79 V2 = 33.6 \0.0001
Other English-speaking 271 0.15 0.10
Other 201 0.11 0.11
Highest level of education Year 11 or below 299 0.16 0.28 V2 = 382.3 \0.0001
Year 12 340 0.19 0.17
Trade certificate 280 0.15 0.24
Diploma 309 0.17 0.09
Bachelor’s degree 420 0.23 0.14
Higher 183 0.10 0.09
ATSI status Yes 153 0.08 0.05 V2 = 43.3 \0.0001
No 1679 0.92 0.95
Marital status Married (registered) 797 0.44 0.49 V2 = 49.9 \0.0001
Separated 55 0.03 0.03
Divorced 153 0.08 0.09
Widowed 66 0.04 0.05
Other 761 0.42 0.34
Australian sex and age distribution (Australian Bureau of Statistics, March 2013) from http://www.abs.gov.au/AUSSTATS/abs@.nsf/
DetailsPage/3101.0Mar%202013?OpenDocument. The GHQ distribution, ATSI status, highest level of education, and country of birth are
derived from the Household, Income and Labour Dynamics in Australia Survey (HILDA, Wave 10), limited to those aged 18 years and over.
Kessler-10 Australian norms were derived from the 2007 Australian National Health Survey [18]
ATSI Aboriginal and Torres Strait Islander
aFor categorical variables, the chi-squared goodness-of-fit test was used to compare observed category frequencies with those expected based on
population proportions; for the continuous K10 score, a one-sample t-test compared the observed K10 mean to the population value reported by
Slade et al. 2011 [18]
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levels within a dimension in Model 1 estimates, the non-
monotonic levels were combined in Model 2. This
restriction has been standardly imposed in previous studies
[24–29].
In a secondary approach, we employed a mixed logit
[30]. In Model 3, it was assumed that coefficients were
drawn from a distribution, allowing for preference
heterogeneity among individuals.
Uisj ¼ aþ cið ÞTIMEisj þ ðbþ giÞX
0
isjTIMEisj þ eisj ð2Þ
Thus, a and the vector of bs now represent population
mean preferences, while ci and gi are individual deviations
around those mean preferences. These deviations were
assumed to be distributed multivariate normal (0,
P
). We
used the mixlogit STATA command [31] to estimate a, the
vector of bs and the standard deviations of c and the vector
of gs, with one adjustment. The standard command limits
the number of parameters drawn from a distribution at 20.
To allow all 31 coefficients (including duration) to be
drawn from a distribution, we used pseudo-random draws
(personal communication, Arne Risa Hole, Department of
Economics, University of Sheffield, 15 June 2015).
To compare models in terms of model fit, Akaike
information criterion (AIC) and Bayesian information cri-
terion (BIC) estimates are presented.
3 Results
3.1 Sample Characteristics and Representativeness
Figure 2 shows the recruitment flow, response rates and
sample sizes for each component of the survey, and
Table 2 shows the sample characteristics relative to pop-
ulation norms. While the sample differed statistically from
the general population in all measured characteristics
except age and sex, differences were generally small (B 3%
in any one category). Notable exceptions were education
(university education over-represented by 18%) and mental
health (Kessler-10 sample mean was in the ‘medium risk’
range of anxiety or depressive disorder while the general
population mean was in ‘low or no risk’ range).
3.2 Utility Estimates
Additional years of life were preferred, and all movements
away from ‘no problems’ in each dimension were valued
negatively (Model 1, Table 3), except level 2 of Social
Functioning (value zero). Moving to worse levels in each
dimension was associated with an absolutely larger coef-
ficient, with only two exceptions. The worst two levels of
the Sleep and Appetite dimensions were not monotonically
ordered, but both violations of monotonicity were small
(0.003 and 0.007, respectively).
Model 2 constrained the coefficients for levels 3 and 4,
respectively, of the Sleep and Appetite dimensions to have
the same coefficient, with very little loss of model fit
(Table 3). The utility decrements for each level of each
dimension from Model 2 are reported in Table 4 with
corresponding 95% confidence intervals, and graphed in
Fig. 3. The largest utility decrements were associated with
physical, role, social and emotion functioning and pain.
Sizeable decrements were associated with nausea, bowel
problems and appetite, while smaller decrements were
associated with problems with sleep and fatigue.
In the mixed logit results (Model 3, online resource 2,
see ESM), the mean of the distributions for each of the
coefficients were generally monotonic, with four excep-
tions. Three dimensions had small positive estimates for
level 2, but none were statistically different from zero:
Social Functioning (p = 0.56), Emotional Functioning
(p = 0.93) and Fatigue (p = 0.81). For Appetite, levels 3
and 4 were non-monotonic (as in Model 1).
Figure 4 compares the utility decrements from Models 1
and 3, showing a strong relationship between correspond-
ing estimates from the conditional logit and mixed logit
models. The coefficients from Model 1 were absolutely
larger than those from Model 3, meaning the spread of the
resultant utility algorithm was slightly larger.
3.3 QLU-C10D Utility Calculation
The utility decrements from Model 2 (Table 4) provide the
weights, wdl, for calculating QLU-C10D scores from QLQ-
C30 responses (Eq. 3). Note that first, QLQ-C30 items must
be converted to QLU-C10D levels, as shown in Table 1. A
utility score of 1 is assigned to patients whose QLQ-C30
scores indicate they are at level 1 of all ten dimensions of the
QLU-C10D. For all other health states, the utility score is 1
minus each utility decrement (wdl) for each level down from
no problems in each of the tenQLU-C10Ddimensions. Thus,
the QLU-C10D utility score for patient p, determined by
their QLU-C10D level l for each dimension d, is
QLUC10Dp ¼ 1
X10
d¼1
wdljQLUC10Ddlp ð3Þ
For example, a health state with quite a lot of problems with
RoleFunctioning, a little problemwithEmotional Functioning,
and a little Nausea, but no problems in any other dimensions,
would be valued at 1- the decrements for Role Functioning
level 3, Emotional Functioning level 2 and Nausea level
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2 = 1- (0.09?0.02? 0.047) = 0.843. By convention, the
health states would be described as 1312111121. The best
possible health state (1111111111) has a value of 1, and the
worst possible state (4444444444) has a value of-0.096.
Appendix 3 in online resource 3 (see ESM) provides
detailed instructions on calculating utility weights for all
the QLU-C10D health states, and provides STATA and
SPSS syntax code to implement this.
When asked about the difficulty of this survey compared
with other surveys they had done, 28% of respondents reported
theDCEquestions to be ‘about the same’ level of difficulty and
39% felt it was ‘harder’.Most (76%) felt the presentation of the
health states was clear or very clear. While 39% felt it was
difficult or very difficult to choose between pairs of health
states, 33% felt it was easy or very easy. Detailed participant
feedback on the DCE task will be published separately.
Table 3 Conditional logit:
Model 1 (unconstrained) and
Model 2 (monotonicity
imposed)
Model 1 Model 2
Mean Coefficienta (robust SE) Coefficienta (robust SE)
Duration Linear 0.555 (0.027)*** 0.552 (0.027)***
Physical functioning 9 Durationa 2 – 0.045 (0.009)*** – 0.044 (0.009)***
3 – 0.084 (0.01)*** – 0.083 (0.01)***
4 – 0.138 (0.01)*** – 0.138 (0.01)***
Role functioning 9 Durationa 2 – 0.014 (0.007)* – 0.013 (0.007)*
3 – 0.051 (0.008)*** – 0.05 (0.007)***
4 – 0.078 (0.007)*** – 0.077 (0.007)***
Social functioning 9 Durationa 2 0 (0.007) 0 (0.007)
3 – 0.036 (0.007)*** – 0.036 (0.007)***
4 – 0.051 (0.007)*** – 0.05 (0.007)***
Emotional functioning 9 Durationa 2 – 0.011 (0.007) – 0.011 (0.007)
3 – 0.037 (0.008)*** – 0.036 (0.008)***
4 – 0.074 (0.007)*** – 0.073 (0.007)***
Pain 9 Durationa 2 – 0.029 (0.007)*** – 0.029 (0.007)***
3 – 0.071 (0.008)*** – 0.071 (0.008)***
4 – 0.086 (0.007)*** – 0.086 (0.007)***
Fatigue 9 Durationa 2 – 0.013 (0.006)** – 0.013 (0.006)**
3 – 0.017 (0.007)** – 0.016 (0.007)**
4 – 0.021 (0.006)*** – 0.02 (0.006)***
Sleep 9 Durationa 2 – 0.019 (0.006)*** – 0.018 (0.006)***
3 – 0.024 (0.007)*** – 0.022 (0.006)***
4 – 0.021 (0.006)*** – 0.022 (0.006)***
Appetite 9 Durationa 2 – 0.017 (0.006)** – 0.015 (0.006)**
3 – 0.032 (0.007)*** – 0.028 (0.006)***
4 – 0.025 (0.006)*** – 0.028 (0.006)***
Nausea 9 Durationa 2 – 0.026 (0.007)*** – 0.026 (0.007)***
3 – 0.038 (0.007)*** – 0.038 (0.007)***
4 – 0.059 (0.007)*** – 0.059 (0.007)***
Bowel problems 9 Durationa 2 – 0.025 (0.006)*** – 0.026 (0.006)***
3 – 0.043 (0.007)*** – 0.043 (0.007)***
4 – 0.052 (0.006)*** – 0.052 (0.006)***
Log-likelihood – 16,930 – 16,930
Parameters 31 29
AIC 33,921 33,919
BIC 34,200 34,180
aThe coefficient for each level of each QOL domain was estimated as the interaction of that level with
duration. Levels combined to ensure monotonicity within each dimension are noted in italics
Levels of statistical significance: ***1%; **5%; *10%
AIC Akaike information criterion, BIC Bayesian information criterion
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4 Discussion
This paper reports the first value set for the QLU-C10D, a
MAUI derived from the EORTC QLQ-C30. This approach
has two important advantages. First, it allows direct
quantification of utility for use in economic evaluation
from responses to the QLQ-C30, a widely used cancer-
specific HRQoL questionnaire. Second, it captures
dimensions related to cancer symptoms that are not inclu-
ded in generic instruments (particularly appetite, nausea
and bowel problems). The main drivers of utility were the
generic dimensions, with the largest utility decrements for
physical, role, social and emotion functioning and pain,
mirroring generic MAUIs. However, sizeable decrements
were associated with cancer-sensitive dimensions, partic-
ularly nausea, bowel problems and appetite. Problems with
sleep and fatigue were smaller, perhaps because minor
problems with sleep and fatigue are relatively common and
therefore considered less important by survey respondents.
It is possible that the size of relative utility weights would
differ for cancer patients with experience of extreme levels
of fatigue and sleep disturbance. The MAUCa Consortium
is exploring this question in a related study currently
underway, sampling Austrian patients and general popu-
lation. Even though the utility decrements for the cancer-
sensitive dimensions were smaller than those for the more
generic dimensions, their inclusion provides a more rele-
vant measure of utility for cancer interventions.
Physical functioning had larger utility decrements than
other dimensions, for each level. In the QLU-C10D,
physical functioning is represented by walking, making it
somewhat comparable to the EQ-5D Mobility and HUI3
Ambulation dimensions. In the HUI3 multi-attribute utility
function, Ambulation does not have the largest utility
decrements for any level [32]. Results from EQ-5D valu-
ation studies are mixed. For example, in Australian valu-
ations of the EQ-5D(3L) using DCE, Mobility had the
largest utility decrement of all dimensions at level 3 but not
level 2 [33], while in Australian EQ-5D(3L) valuations
using time trade-off (TTO), Anxiety/Depression and Pain/
Discomfort had the largest utility decrements at level 3,
and at level 2 Mobility had the second lowest utility
decrement [34]. Why might ability to walk have the largest
impact on utility in the current study? First, physical
functioning appeared as the first dimension in the choice
set, as in the QLQ-C30 parent questionnaire. However, we
have previously investigated and dismissed order effect
after randomised testing in DCEs for both QLU-C10D [11]
and EQ-5D-5L [35]. Second, due to the complexity of the
level descriptors, physical functioning appeared in the DCE
as two attributes, even though it was a single four-level
dimension in the DCE experimental design and analysis. A
useful comparator here is the EORTC-8D, where Physical
Functioning was presented as a single five-level dimension
(representing the same QLQ-C30 long/short walk items as
in the QLU-C10D) [27]. It had the third largest utility
decrement for the worst level (exceeded by Social and
Emotional Functioning) and the second largest for level 2
(exceed by Pain). While country is a confounder of this
Table 4 Utility decrements used in the QLU-C10D utility algorithm
Dimension Level Utility decrement, wdl (95% CI)
Physical functioning 1 0
2 – 0.081 (– 0.051 to – 0.110)
3 – 0.151 (– 0.120 to – 0.182)
4 – 0.250 (– 0.220 to – 0.280)
Role functioning 1 0
2 – 0.024 (0.001 to – 0.049)
3 – 0.090 (– 0.066 to – 0.114)
4 – 0.139 (– 0.117 to – 0.161)
Social functioning 1 0
2 0.000 (0.024 to – 0.025)
3 – 0.064 (– 0.040 to – 0.089)
4 – 0.091 (– 0.070 to – 0.112)
Emotional functioning 1 0
2 – 0.020 (0.003 to – 0.043)
3 – 0.066 (– 0.041 to – 0.091)
4 – 0.133 (– 0.112 to – 0.155)
Pain 1 0
2 – 0.053 (– 0.029 to – 0.078)
3 – 0.129 (– 0.105 to – 0.153)
4 – 0.155 (– 0.133 to – 0.177)
Fatigue 1 0
2 – 0.023 (– 0.001 to – 0.045)
3 – 0.029 (– 0.006 to – 0.053)
4 – 0.037 (– 0.016 to – 0.058)
Sleep 1 0
2 – 0.033 (– 0.012 to – 0.054)
3 – 0.039 (– 0.020 to – 0.059)
4 – 0.039 (– 0.020 to – 0.059)
Appetite 1 0
2 – 0.028 (– 0.006 to – 0.049)
3 – 0.050 (– 0.030 to – 0.070)
4 – 0.050 (– 0.030 to – 0.070)
Nausea 1 0
2 – 0.047 (– 0.025 to – 0.070)
3 – 0.068 (– 0.044 to – 0.092)
4 – 0.107 (– 0.086 to – 0.127)
Bowel problems 1 0
2 – 0.047 (– 0.025 to – 0.068)
3 – 0.078 (– 0.054 to – 0.102)
4 – 0.094 (– 0.073 to – 0.115)
From Model 2, conditional logit, monotonicity imposed
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comparison, this issue cannot be ruled out as a driver of the
effect, but will be resolved soon as UK valuations of the
QLU-C10D are underway. Finally, the QLU-C10D Physi-
cal Functioning dimension covers a large range of mobility
with four levels reflecting the combined range of the two
QLQ-C30 walking items (see Table 1), while other
dimensions are based on the range in only one item. It may
therefore be appropriate that the utility decrements are
correspondingly large.
In similar studies, initial models have contained some
inconsistent orderings of utility decrements within dimensions,
particularly for dimensions with small utility impacts [24–29].
Consistent with previous studies, we imposed constraints to
remove non-monotonicities. This did not reduce model fit
markedly, and avoids perverse results in QALY calculations.
Anchors at one (full health) and zero (death) are
imposed by the QALY model, but there is no natural
anchor for the pits state (worst possible health state). The
QLU-C10D pits state value is -0.095. This is considerably
lower than the 0.29 pits state value for the QLU-C10D’s
precursor, EORTC-8D [27], which has eight of the ten
QLU-C10D dimensions (four with exactly the same items
and levels as the QLU-C10D, four that differ slightly), but
lacks Sleep and Appetite. In our study, the worst levels of
Sleep and Appetite had a combined utility decrement of
0.09, so the difference in content explains some of the
difference in pits state values. Since the EORTC-8D was
valued with TTO in the United Kingdom (UK) general
population, valuation method and country likely explain
much of the remainder, as both instruments share a simple
additive utility function. The values of the pits state in the
original UK and Australian EQ-5D(3L) TTO studies were
-0.594 [36] and -0.217 [34], respectively, and in the
Australian EQ-5D(3L) DCE study it was -0.516 [33].
Variations in the value of health states, including the pits
state, are driven by several factors [37], including country-
specific cultural differences in attitudes to trading between
mortality and morbidity, different health state classification
system content, valuation method and utility functional
form. Arguably, a lower pits state value means a greater
range in a value set which may lead to greater differences
between interventions in CUA. A related issue is sensitivity
to mild impairments. Values for health states with level 2
across all dimensions were 0.464 for the QLU-C10D
(Australian DCE) and 0.715 for the EORTC-8D (UK
TTO). Assessing the sensitivity of the QLU-C10D to dif-
ferences in mild and extreme QOL impacts, and comparing
this with other candidate MAUIs, are important issues for
future research.
The DCE method has emerged as an alternative to TTO
and standard gamble (SG) methods for valuation of health
outcomes in the past decade, and has now been used in a
Fig. 3 Australian Utility
Algorithm (derived from Model
2 conditional logit,
monotonicity imposed). PF
physical functioning, RF role
functioning, SF social
functioning, EF emotional
functioning, PA Pain, FA
fatigue, TS sleep, AP appetite,
NA nausea, BO bowel problems
Fig. 4 Scatter plot of utility decrements generated by conditional
logit and mixed logit. Dotted line represents line of best fit, solid line
represents line of equality
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number of studies [6, 20, 21, 33, 38, 39]. The discrete
choice method is attractive for several reasons: it is
embedded in a strong theoretical measurement framework;
it utilises well established statistically robust experimental
design and modelling methods; it is based on a relatively
simple judgmental task; it is feasible with online recruit-
ment and data collection. The use of DCEs to value health
states is maturing, but still presents some challenges. While
the judgmental task is simple relative to TTO and SG, thus
allowing survey respondents to consider a larger number of
attributes, the 12 attributes in the current study is a rela-
tively large number. This study confirms the QLU-C10D
valuation methods experiment in finding this is feasible for
respondents [5]. We reduced cognitive challenge firstly by
allowing only four dimensions to differ in each choice set
and secondly by presenting choice sets in the format pre-
ferred by participants in the methods experiment, using
yellow highlighting to identify differences between situa-
tions A and B [5]. Allowing only some dimensions to differ
across choice sets has the additional advantage of requiring
respondents who employ heuristics such as considering a
single attribute to trade off between other attributes. We
designed an experiment with 960 choice sets that would
maximise statistical efficiency in estimating utility
parameters. This meant the survey included some health
states that might seem rather unlikely to respondents, such
as severe vomiting yet no problems with social function.
However, we note that in the patient-reported QLQ-
C30 data used to derive the QLU-C10D health state clas-
sification system, at least one patient reported each pair-
wise combination of levels [4].
We used two modelling approaches, conditional logit
and mixed logit, which yielded similar mean utility
decrements. We have chosen conditional logit (Model 2) as
the basis for calculating utilities for CUA for the following
reasons: (i) for economic evaluation, we are generally most
interested in the mean response, so preference hetero-
geneity is a secondary concern; (ii) to our knowledge, there
remains uncertainty about the appropriate distributional
assumptions for the mixed logit.
This study has several strengths and some limitations. It
provides a preference-based measure for calculating utilities
for the QLQ-C30, which is theoretically and empirically
stronger than using mappings of the EORTC QLQ-C30 to
other preference-based utility measures [40]. The develop-
ment of the health state classification system was psychome-
trically thorough [4]. The valuation survey sample was large,
with quota sampling achieving population representativeness
for age and sex. The extent to which non-representativeness
on the other measured sociodemographic variables is a limi-
tation is as yet unknown, and will be explored in future
researching by pooling valuation data across the MAUCa
Consortium. We established the feasibility of our DCE
method [5], and havenoted its strengths and limitations above.
We used modelling approaches appropriate to our data
structure and analysis purpose. Our choice of a monotonic
main-effects model for calculating utility is readily accessible
for a range of end users, clinically interpretable and consistent
with the EORTC quality-of-life conceptual model.
The appropriateness of disease-specific utility weights
for CUA is debated by health economists [41]. Conven-
tionally, generic MAUIs such as the EQ-5D are used,
primarily to enable comparability across health conditions
and interventions. However, the capacity of generic
instruments to capture clinically relevant differences in
cancer is also debated [42–44]. Arguably, the QLU-C10D
should provide a more cancer-sensitive measure of utility
than provided by generic MAUIs, although this is yet to be
tested empirically. Further, data on generic utility measures
may not always be available. The QLU-C10D enables
utility values to be retrospectively generated from the
wealth of existing QLQ-C30 data, thus facilitating eco-
nomic evaluation from existing studies. It is anticipated
that the QLU-C10D will have good psychometric proper-
ties, and future research will examine this, as well as
assessing its performance relative to generic MAUIs.
The QLU-C10D has been developed by the MAUCa Con-
sortium in collaboration with the EORTC QOL Group. A key
strength of the Consortium’s approach is the use of identical
valuation methods across countries, creating a unique oppor-
tunity to explore predictors of health outcome values, including
country, age, sex, education and health status of valuation
survey respondents—this will be done in future analyses.
The QLU-C10D is endorsed by the EORTC QOL Group,
and supersedes the EORTC-8D. Notably, the development
of the health state classification system of the EORTC-8D
was based on data from 655 multiple myeloma patients,
while that of the QLU-C10D was informed by a much larger
(n = 2616) and more diverse sample: 13 countries, 15 pri-
mary cancer types, localised/regional (n = 1037) and
recurrent/metastatic stages (n = 1579) [4]. The EORTC
QOL Group now has stewardship of the QLU-C10D, being
responsible for all aspects of its management, developing
and maintaining information regarding administration,
scoring and interpretation, and housing relevant materials on
the EORTC QOL website. This will make the QLU-C10D
widely available for use prospectively and retrospectively,
and thereby facilitate the incorporation of quality of life into
healthcare decision-making for cancer care.
5 Conclusions
CUA represents a major part of the reimbursement process
in many countries. In Australia, the government guidelines
for preparing submissions to the Pharmaceutical Benefits
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Advisory Committee (PBAC) favour direct estimation of
utilities over mapping, do not mandate a particular MAUI
but prefer Australian-based preference weights and
encourage the use of patient-reported outcomes/MAUIs
that capture all important disease- or condition-specific
factors [45; pages 37, 77]. Based on the experience of RV
and RN serving on PBAC and its subcommittees, sub-
missions for cancer interventions frequently present QLQ-
C30 data. Therefore, the value set presented here will aid
Australian resource allocation decisions. Further, the
methods presented in this paper provide a template for
further international valuations of the QLU-C10D. A
number of these are underway, using exactly the same DCE
design, presentation format and analysis, including Austria,
Canada, France, Germany, Poland, the UK and the US,
enabling assessment of international comparability of
preferences for cancer-specific health states.
Data Availability Statement The dataset generated
during the current study will not be publicly available until
all planned analyses are complete (see Sect. 4). For
updates, please contact the EORTC Quality of Life Group
Health Technology Committee.
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